Last reviewed · How we verify
Cessation-Phase Varenicline
Cessation-Phase Varenicline, marketed by the VA Office of Research and Development, is a smoking cessation aid with a key composition patent expiring in 2028. The drug's primary strength lies in its established market presence and mechanism of action, which differentiates it from other smoking cessation therapies. The primary risk is the potential increase in competition following the 2028 patent expiry.
At a glance
| Generic name | Cessation-Phase Varenicline |
|---|---|
| Also known as | Chantix |
| Sponsor | VA Office of Research and Development |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Varenicline for Smoking Reduction in Veterans Not Ready To Quit (PHASE4)
- Varenicline for Nicotine Vaping Cessation in Adolescents (PHASE4)
- Nicotine Withdrawal Symptoms and Smoking Relapse (NA)
- TOBacco STOP in Chronic Obstructive Pulmonary Disease-Trial - Study Protocol (PHASE4)
- Comparison of Varenicline and Placebo for Smoking Cessation in Schizophrenia (PHASE2)
- Extended (6-Week) Varenicline Preloading: Does it Facilitate Smoking Reduction and Cessation? (PHASE4)
- Multimodal Cue Exposure Therapy for Smoking Cessation (PHASE2)
- PRecision Interventions for SMoking in the SCCS (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Cessation-Phase Varenicline CI brief — competitive landscape report
- Cessation-Phase Varenicline updates RSS · CI watch RSS
- VA Office of Research and Development portfolio CI